Published in Antivir Chem Chemother on November 01, 2004
Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem Rev (2014) 1.13
Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother (2006) 0.80
Single-dose pharmacokinetics and metabolism of [14C]remofovir in rats and cynomolgus monkeys. Antimicrob Agents Chemother (2005) 0.78
The treatment of chronic hepatitis B: Focus on adefovir-like antivirals. Ther Clin Risk Manag (2008) 0.76
Development and Validation of a Sensitive LC-MS-MS Method for the Determination of Adefovir in Human Serum and Urine: Application to a Clinical Pharmacokinetic Study. J Chromatogr Sci (2015) 0.75
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science (2014) 2.11
Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology (2009) 1.91
Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology (2002) 1.81
Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J Virol (2002) 1.51
Prodrugs of phosphates and phosphonates. J Med Chem (2008) 1.44
A plant-specific calreticulin is a key retention factor for a defective brassinosteroid receptor in the endoplasmic reticulum. Proc Natl Acad Sci U S A (2009) 1.40
RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res (2009) 1.38
The role of OsBRI1 and its homologous genes, OsBRL1 and OsBRL3, in rice. Plant Physiol (2006) 1.32
Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett (2007) 1.30
Conserved endoplasmic reticulum-associated degradation system to eliminate mutated receptor-like kinases in Arabidopsis. Proc Natl Acad Sci U S A (2010) 1.22
In vitro RNA replication directed by replicase complexes isolated from the subgenomic replicon cells of hepatitis C virus. J Virol (2003) 1.20
Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem (2001) 1.19
Crystal structure of complete rhinovirus RNA polymerase suggests front loading of protein primer. J Virol (2005) 1.17
HCV RNA-dependent RNA polymerase as a target for antiviral development. Curr Opin Pharmacol (2002) 1.13
Selection of 3'-template bases and initiating nucleotides by hepatitis C virus NS5B RNA-dependent RNA polymerase. J Virol (2002) 1.13
Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther (2007) 1.13
Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2006) 1.12
Synthesis and antiviral evaluation of a mutagenic and non-hydrogen bonding ribonucleoside analogue: 1-beta-D-Ribofuranosyl-3-nitropyrrole. Biochemistry (2002) 1.11
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2006) 1.08
Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. Diabetes (2006) 1.05
The amino-terminal domain of bovine viral diarrhea virus Npro protein is necessary for alpha/beta interferon antagonism. J Virol (2006) 1.03
Mutations in NS5B polymerase of hepatitis C virus: impacts on in vitro enzymatic activity and viral RNA replication in the subgenomic replicon cell culture. Virology (2002) 1.00
Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir Chem Chemother (2003) 1.00
Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. Antivir Chem Chemother (2005) 0.99
Hepatitis C virus therapies: current treatments, targets and future perspectives. Antivir Chem Chemother (2003) 0.99
Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. Antimicrob Agents Chemother (2003) 0.98
Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother (2003) 0.98
ARF1 and GBF1 generate a PI4P-enriched environment supportive of hepatitis C virus replication. PLoS One (2012) 0.98
Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure. Bioorg Med Chem Lett (2006) 0.97
Sensitive and specific LC-MS/MS method for the simultaneous measurements of viramidine and ribavirin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.96
Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. Antimicrob Agents Chemother (2003) 0.94
Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes. J Am Chem Soc (2007) 0.94
Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design. J Antimicrob Chemother (2003) 0.93
Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase. Mini Rev Med Chem (2005) 0.93
The Arabidopsis homolog of the mammalian OS-9 protein plays a key role in the endoplasmic reticulum-associated degradation of misfolded receptor-like kinases. Mol Plant (2012) 0.93
PtdIns(4)P regulates retromer-motor interaction to facilitate dynein-cargo dissociation at the trans-Golgi network. Nat Cell Biol (2013) 0.92
Beyond nutrients: food-derived microRNAs provide cross-kingdom regulation. Bioessays (2012) 0.92
Interferon-alpha2b secretion by adenovirus-mediated gene delivery in rat, rabbit, and chimpanzee results in similar pharmacokinetic profiles. Toxicol Appl Pharmacol (2002) 0.91
A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2006) 0.90
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res (2013) 0.90
Adenosine kinase inhibitors. 3. Synthesis, SAR, and antiinflammatory activity of a series of l-lyxofuranosyl nucleosides. J Med Chem (2003) 0.90
Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response. J Virol (2005) 0.90
Design, synthesis, and antiviral activity of adenosine 5'-phosphonate analogues as chain terminators against hepatitis C virus. J Med Chem (2005) 0.89
Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers (2012) 0.89
Viability of poliovirus/rhinovirus VPg chimeric viruses and identification of an amino acid residue in the VPg gene critical for viral RNA replication. J Virol (2003) 0.89
Structure-activity relationship (SAR) studies of quinoxalines as novel HCV NS5B RNA-dependent RNA polymerase inhibitors. Bioorg Med Chem Lett (2007) 0.87
Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver. Antimicrob Agents Chemother (2004) 0.87
Cyclic monophosphate prodrugs of base-modified 2'-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication. Bioorg Med Chem Lett (2007) 0.87
Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antivir Chem Chemother (2004) 0.87
Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother (2005) 0.86
6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4-dihydroquinolines as HIV integrase inhibitors. Bioorg Med Chem Lett (2010) 0.86
Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase. J Med Chem (2010) 0.86
Modulation of cardiac remodeling by adenosine: in vitro and in vivo effects. Mol Cell Biochem (2003) 0.85
SOCS1 abrogates IFN's antiviral effect on hepatitis C virus replication. Antiviral Res (2012) 0.85
Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir. J Clin Pharmacol (2005) 0.84
Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors. J Med Chem (2008) 0.84
Promising candidates for the treatment of chronic hepatitis C. Expert Opin Investig Drugs (2003) 0.84
Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol (2004) 0.84
Narrow bandpass tunable terahertz filter based on photonic crystal cavity. Appl Opt (2012) 0.83
Hepatitis C replication inhibitors that target the viral NS4B protein. J Med Chem (2013) 0.83
Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. J Clin Pharmacol (2005) 0.82
Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors. Bioorg Med Chem Lett (2006) 0.82
Ab initio quantum mechanics-based free energy perturbation method for calculating relative solvation free energies. J Comput Chem (2007) 0.82
Agents in clinical development for the treatment of chronic hepatitis B. Expert Opin Investig Drugs (2003) 0.82
Hepatitis C virus NS5A hijacks ARFGAP1 to maintain a phosphatidylinositol 4-phosphate-enriched microenvironment. J Virol (2014) 0.82
Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes. Handb Exp Pharmacol (2011) 0.82
Adenosine kinase inhibitors. 5. Synthesis, enzyme inhibition, and analgesic activity of diaryl-erythro-furanosyltubercidin analogues. J Med Chem (2005) 0.82
Terahertz gas sensing based on a simple one-dimensional photonic crystal cavity with high-quality factors. Appl Opt (2014) 0.81
Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects. Antimicrob Agents Chemother (2010) 0.81
Synthesis of 2'-beta-C-methyl toyocamycin and sangivamycin analogues as potential HCV inhibitors. Bioorg Med Chem Lett (2005) 0.81
Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. J Med Chem (2008) 0.81
Relative binding affinities of fructose-1,6-bisphosphatase inhibitors calculated using a quantum mechanics-based free energy perturbation method. J Am Chem Soc (2007) 0.80
HepDirect prodrugs for targeting nucleotide-based antiviral drugs to the liver. Curr Opin Investig Drugs (2006) 0.80
Free energy calculations to estimate ligand-binding affinities in structure-based drug design. Curr Pharm Des (2014) 0.80
Identification of novel, selective and potent Chk2 inhibitors. Bioorg Med Chem Lett (2006) 0.80
Discovery of fructose-1,6-bisphosphatase inhibitors for the treatment of type 2 diabetes. Curr Opin Drug Discov Devel (2007) 0.80
Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother (2006) 0.80
Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: convergence of structure-based drug design and X-ray crystallographic study. Bioorg Med Chem Lett (2007) 0.79
Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist. Drug Metab Dispos (2008) 0.79
Structure of human uridine-cytidine kinase 2 determined by SIRAS using a rotating-anode X-ray generator and a single samarium derivative. Acta Crystallogr D Biol Crystallogr (2005) 0.79
Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy. Curr Drug Targets Infect Disord (2003) 0.79
Synthesis of 9-(2-beta-C-methyl-beta-d-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication. Bioorg Med Chem Lett (2005) 0.79
Antiviral efficacy upon administration of a HepDirect prodrug of 2'-C-methylcytidine to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother (2011) 0.79
Liver-targeted prodrugs of 2'-C-methyladenosine for therapy of hepatitis C virus infection. J Med Chem (2007) 0.79
6-Hydrazinopurine 2'-methyl ribonucleosides and their 5'-monophosphate prodrugs as potent hepatitis C virus inhibitors. Bioorg Med Chem Lett (2007) 0.79
Solid-phase parallel synthesis of 4-beta-D-ribofuranosylpyrazolo[4,3-d]pyrimidine nucleosides. Nucleosides Nucleotides Nucleic Acids (2005) 0.79
Slow light in a dielectric waveguide with negative-refractive-index photonic crystal cladding. Opt Express (2008) 0.79
Fructose-1,6-bisphosphatase inhibitors. 1. Purine phosphonic acids as novel AMP mimics. J Med Chem (2009) 0.79
In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother (2013) 0.79
Viramidine demonstrates better safety than ribavirin in monkeys but not rats. Drug Chem Toxicol (2004) 0.79
Ultra sensitive method for the determination of 9-(2-phosphonylmethoxyethyl)adenine in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.79
Advances in binding free energies calculations: QM/MM-based free energy perturbation method for drug design. Curr Pharm Des (2013) 0.78